Preliminary results from an ongoing phase 3 trial (ARCHER 1009) in unselected patients with advanced NSCLC suggest similar PFS with dacomitinib versus erlotinib as second- or third-line therapy in the coprimary populations, all patients (2.6 vs. 2.6 months; P = 0.229) and KRAS wild-type patients (2.6 vs. 2.6 months; P = 0.587); OS and outcomes for patients with EGFR mutation are not mature 42. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.